STML - Stemline Therapeutics, Inc.
| Previous Close | 15.92 |
| Open | 15.73 |
| Bid | 15.07 x 800 |
| Ask | 15.11 x 800 |
| Day's Range | 14.94 - 15.87 |
| 52 Week Range | 7.82 - 18.00 |
| Volume | 271,593 |
| Avg. Volume | 512,128 |
| Market Cap | 600.948M |
| Beta (3Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.03 |
| Earnings Date | Aug 7, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.43 |
- Insider Monkey•5 days ago
Hedge Funds Have Never Been This Bullish On Stemline Therapeutics Inc (STML)
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
- GlobeNewswire•7 days ago
Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress
NEW YORK, June 17, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- GlobeNewswire•11 days ago
Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15
NEW YORK, June 13, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- Simply Wall St.•21 days ago
When Will Stemline Therapeutics, Inc. (NASDAQ:STML) Turn A Profit?
Stemline Therapeutics, Inc.'s (NASDAQ:STML): Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical...
- GlobeNewswire•21 days ago
Stemline Therapeutics Announces ASCO Presentation of ELZONRIS Phase 2 Clinical Data in CMML and MF; Provides Next Steps for CMML Program
NEW YORK, June 03, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- Thomson Reuters StreetEvents•28 days ago
Edited Transcript of STML earnings conference call or presentation 10-May-19 12:00pm GMT
Q1 2019 Stemline Therapeutics Inc Earnings Call
- GlobeNewswire•last month
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress
NEW YORK, May 20, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- GlobeNewswire•last month
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting
NEW YORK, May 16, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- Benzinga•last month
Wedbush: Trajectory For Stemline Therapeutics' Blood Cancer Drug Priced Into Stock
Stemline Therapeutics Inc (NASDAQ: STML ) reported a wider first-quarter net loss per share Friday, dragged by higher R&D expenses, which nearly tripled from a year ago. The Analyst Wedbush analyst David ...
Motley Fool•last monthStemline Therapeutics, Inc. (STML) Q1 2019 Earnings Call Transcript
STML earnings call for the period ending March 31, 2019.
- Zacks•last month
Stemline Therapeutics (STML) Reports Q1 Loss, Tops Revenue Estimates
Stemline Therapeutics (STML) delivered earnings and revenue surprises of -8.96% and 93.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Stemline Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the New York-based company said it had a loss of 73 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•last month
Stemline Therapeutics Reports First Quarter 2019 Financial Results
Net revenue for ELZONRIS was $5.05 million for the first quarterConference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, May 10, 2019 -- Stemline.
- GlobeNewswire•2 months ago
Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019
NEW YORK, May 08, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- GlobeNewswire•2 months ago
Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results
Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the pivotal trial results of ELZONRIS™ (tagraxofusp), a targeted therapy directed to CD123, in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) have been published in the April 25 issue of the New England Journal of Medicine. ELZONRIS (tagraxofusp-erzs) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of BPDCN in adults and pediatric patients two years and older, and is commercially available in the U.S. Andrew Lane, M.D., Ph.D., Assistant Professor at Harvard Medical School and Dana-Farber Cancer Institute and a co-lead author of the manuscript, offered: “This publication by the New England Journal of Medicine highlights the increasing recognition of BPDCN in the medical community.
- Simply Wall St.•2 months ago
Announcing: Stemline Therapeutics (NASDAQ:STML) Stock Increased An Energizing 150% In The Last Three Years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a really great company, you can more than double your money. For instance the Stemline Therapeutics, In...
- GlobeNewswire•3 months ago
Research Report Identifies Oracle, Realty Income, Stemline Therapeutics, WhiteHorse Finance, EverQuote, and Sanderson Farms with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•3 months ago
Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference
NEW YORK, March 18, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- Associated Press•3 months ago
Stemline Therapeutics: 4Q Earnings Snapshot
NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Friday reported a loss of $26.6 million in its fourth quarter. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 72 cents per share.
- GlobeNewswire•3 months ago
Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results
NEW YORK, March 15, 2019 -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel.
- GlobeNewswire•3 months ago
Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline
Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that it has exclusively licensed worldwide rights to develop and commercialize a novel, oral, selective small molecule RET (rearranged during transfection) kinase inhibitor from the CRT Pioneer Fund LP, a £70 million specialist oncology investment fund managed by Sixth Element Capital, a UK based fund manager. The RET inhibitor was rationally designed by scientists at Cancer Research UK Manchester Institute at the University of Manchester (United Kingdom). SL-1001 is an oral RET kinase inhibitor that has demonstrated potent, selective, preclinical anti-cancer activity, both in vitro and in vivo, in RET-driven tumor models.
- GlobeNewswire•4 months ago
Stemline Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference
Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein, M.D., Stemline’s CEO, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019 at 4:50 PM ET at the Marriott Copley Place in Boston, MA. The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor. ELZONRIS (tagraxofusp), a CD123-directed cytotoxin, was approved by the Food and Drug Administration (FDA) on December 21, 2018 for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- Simply Wall St.•4 months ago
Is Stemline Therapeutics, Inc. (NASDAQ:STML) Excessively Paying Its CEO?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Ivan Bergstein became the CEO of Stemline Therapeutics, Inc. (NASDAQ:STML)Read More...
- GlobeNewswire•5 months ago
Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)
Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the European Medicines Agency (EMA) has completed its validation of the Marketing Authorization Application (MAA) for ELZONRIS™ (tagraxofusp-erzs). Stemline submitted the MAA earlier this month seeking approval of ELZONRIS for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Under European Union legislation, a medicinal product of major public health interest may be reviewed under an accelerated assessment procedure.
- GlobeNewswire•5 months ago
Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics — Fundamental Analysis, Key Performance Indications
NEW YORK, Jan. 24, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
